Preferred Salvage Regimen for Relapsed/Refractory CD22+ B-ALL
For adults with relapsed/refractory CD22-positive B-ALL, inotuzumab ozogamicin (InO) is the preferred salvage agent, dosed at 0.8 mg/m² on day 1, followed by 0.5 mg/m² on days 8 and 15 for cycle 1, with subsequent cycles using 0.5 mg/m² on days 1,8, and 15. 1
Evidence-Based Rationale
The FDA-approved InO regimen demonstrated superior outcomes in the pivotal INO-VATE phase III trial, achieving:
- Complete remission rate of 80.7% versus 29.4% with standard chemotherapy (P < 0.001)
- MRD negativity in 78.4% versus 28.1% with chemotherapy (P < 0.001)
- Improved overall survival (HR 0.75, P = 0.0105) 1
This represents the highest quality evidence from a randomized controlled trial specifically in the relapsed/refractory setting.
Optimal Combination Approaches
For Younger, Fit Patients
Mini-hyper-CVD plus InO with sequential blinatumomab achieves the best outcomes:
- Overall response rate of 80% with 57% complete remission
- MRD negativity in 83% of responders
- 3-year overall survival of 33% (55% in favorable subgroups with CD22 ≥70% and no adverse cytogenetics) 2
The regimen consists of:
- Reduced-intensity chemotherapy: 50% dose reduction of cyclophosphamide and dexamethasone, no anthracycline, 75% methotrexate reduction, cytarabine 0.5 g/m² × 4 doses
- InO: 1.3-1.8 mg/m² cycle 1, then 1.0-1.3 mg/m² subsequent cycles 3
- Sequential blinatumomab consolidation after 4 cycles of mini-hyper-CVD/InO 2
For Older or Less Fit Patients
InO monotherapy remains highly effective with lower toxicity burden, particularly appropriate for patients ≥60 years or those with comorbidities 1.
Critical Safety Considerations
Veno-Occlusive Disease (VOD) Prevention
VOD occurred in 11% of InO-treated patients in INO-VATE, predominantly post-transplant 1. Mandatory risk mitigation strategies include:
- Limit InO to maximum 2 cycles before allogeneic transplant
- Monitor bilirubin closely before conditioning
- Avoid dual alkylating agent conditioning regimens
- Use VOD prophylaxis with ursodeoxycholic acid or defibrotide
- Exclude patients with pre-existing liver disease (portal hypertension, cirrhosis) 1
The dose-dense mini-hyper-CVD/InO/blinatumomab approach reduced VOD rates from 13% to 3% by using lower InO doses and sequential blinatumomab 2.
Other Grade 3-4 Toxicities
- Prolonged thrombocytopenia (81%)
- Infections (52-69%)
- Hyperglycemia (54%) 3
Alternative Considerations
Blinatumomab
While blinatumomab showed superiority over chemotherapy in the TOWER trial (44% vs 25% CR rate, median OS 7.7 vs 4.0 months) 1, InO achieves higher complete remission rates (80.7%) and is preferred for high disease burden settings where cytoreduction is critical 4.
Blinatumomab is most appropriate for:
- Low disease burden/MRD-positive disease
- Patients with preserved T-cell function
- Sequential consolidation after InO induction 4
Standard Chemotherapy
Recent comparative data show chemotherapy achieves similar 10-month median OS as novel agents in first salvage 5, but this approach is only reasonable for very young, fit patients where preserving novel agents for subsequent relapses may be strategic. However, given InO's superior CR rates and MRD negativity, this represents suboptimal initial management for most patients.
Bridge to Transplant Strategy
46% of patients receiving mini-hyper-CVD/InO/blinatumomab successfully bridged to allogeneic transplant 2. The combination approach optimizes transplant eligibility by achieving deep MRD negativity rapidly.
Key timing consideration: Ensure adequate interval (typically 2-3 months) between last InO dose and transplant conditioning to minimize VOD risk 1.
Common Pitfalls to Avoid
- Using InO beyond 2 cycles pre-transplant - dramatically increases VOD risk
- Selecting busulfan or dual-alkylator conditioning after InO exposure
- Treating patients with baseline liver disease with InO
- Failing to monitor bilirubin before transplant conditioning
- Using InO in patients with CD22 expression <70% - outcomes significantly worse 2
Treatment Algorithm
Step 1: Confirm CD22 positivity and assess CD22 expression level (optimal ≥70%)
Step 2: Evaluate liver function and exclude chronic liver disease
Step 3: Assess disease burden and patient fitness
- High burden + fit patient → Mini-hyper-CVD + InO + sequential blinatumomab
- High burden + older/unfit → InO monotherapy
- Low burden/MRD-positive → Consider blinatumomab first-line
Step 4: If transplant candidate, limit InO to 2 cycles maximum
Step 5: Implement VOD prophylaxis for all patients proceeding to transplant
This algorithmic approach prioritizes the highest quality guideline evidence 3, 1 while incorporating real-world safety data 2 to optimize both efficacy and quality of life outcomes.